Medicines for Mixed connective tissue disease

What it is

Mixed connective tissue disease (MCTD) is an autoimmune condition that has overlapping features of several other connective tissue diseases — namely systemic lupus erythematosus (lupus), systemic sclerosis (scleroderma), and inflammatory muscle disease (myositis) — occurring together, along with a specific antibody found in the blood (anti-U1-RNP). Because it combines features of these conditions, its symptoms can be varied. Common features include Raynaud's phenomenon (fingers and toes changing colour and going numb in the cold, often an early feature), swollen "puffy" fingers or hands, joint pain and swelling (arthritis), muscle pain and weakness, and general symptoms such as tiredness. Over time, features of the individual conditions can develop, and it can affect internal organs — importantly including the lungs (where a particular concern is a form of raised blood pressure in the lung arteries, pulmonary hypertension) and others — which is why monitoring is important. MCTD varies greatly between people and over time, and in some it may evolve to more closely resemble one of the individual conditions. Because it involves the immune system and can affect organs, it is managed by specialists, and treatment is tailored to the particular features and their severity.

How it is treated

MCTD is diagnosed and managed by specialists (usually rheumatologists), based on the combination of clinical features and the presence of the characteristic antibody, along with tests to assess which organs are involved. Because it is so variable, treatment is individualised and directed at the specific features present and their severity, rather than a single fixed regimen. Milder features (such as Raynaud's, joint pain, and puffy hands) are managed with measures for those problems — for example keeping warm and, if needed, medicines for Raynaud's, and anti-inflammatory or other medicines for joint symptoms. More significant inflammation (such as arthritis, muscle inflammation, or organ involvement) is treated with medicines that calm the immune system, such as steroids and other immune-modulating (disease-modifying) medicines, chosen according to what is affected. A particularly important part of care is monitoring for organ involvement, especially the lungs — including screening for pulmonary hypertension, which is a serious potential complication that benefits from early detection and treatment. Regular follow-up tracks the condition, which can change over time. The reassuring message is that mixed connective tissue disease, though a complex autoimmune condition, is managed effectively by specialists — treatment is tailored to control the symptoms and inflammation and protect the organs, and monitoring (especially of the lungs) allows early treatment of complications.